Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00594165 · ClinicalTrials.gov registry record · Phase 3
An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Early-Stage Parkinson's Disease.
A Phase 3 study of Early-Stage Parkinson's Disease, sponsored by UCB Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 217
- Enrollment target
- 20
- Study locations
NCT00594165 is a Phase 3 study of Early-Stage Parkinson's Disease that has completed, run by UCB Pharma. The registered enrollment target is 217 participants. The trial reports 20 study locations across 13 states.
The verdict
NCT00594165, a Phase 3 study of Early-Stage Parkinson's Disease, has completed, sponsored by UCB Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 217 participants
- Enrollment target
- 20
- Study locations
Study Summary
The objective of this open-label extension is to assess the safety and tolerability of long-term treatment of the rotigotine patch in subjects with early-stage idiopathic Parkinson's disease.
Conditions Studied
Interventions
- DRUG Rotigotine
Study Locations (20)
Arizona
- - Peoria
- - Phoenix
- - Tucson
California
- - Fountain Valley
- - Fresno
- - Los Angeles
Florida
- - Miami
- - Pompano Beach
- - Sunrise
Connecticut
- - Danbury
- - New Haven
Colorado
- - Englewood
Georgia
- - Atlanta
Illinois
- - Chicago
Indiana
- - Fort Wayne
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 217 participants |
| Start Date | 2002-06 |
| Est. Completion | 2008-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00594165
The ClinicalTrials.gov registry entry for NCT00594165 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 217 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Pharma, which has 100 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Early-Stage Parkinson's Disease appearing as the primary indexed condition, and to 1 intervention - of which Rotigotine is the first listed.
NCT00594165 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Arizona, California, Florida.
Frequently Asked Questions
What is clinical trial NCT00594165 about?
NCT00594165 is a clinical study titled "An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Early-Stage Parkinson's Disease.". The objective of this open-label extension is to assess the safety and tolerability of long-term treatment of the rotigotine patch in subjects with early-stage idiopathic Parkinson's disease.
What is the current status of trial NCT00594165?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 217 participants. The study started on 2002-06. Estimated completion is 2008-11.
What conditions does trial NCT00594165 study?
This clinical trial studies the following conditions: Early-Stage Parkinson's Disease.
What interventions are being tested in trial NCT00594165?
The interventions under investigation include: Rotigotine (DRUG).
Who is sponsoring clinical trial NCT00594165?
This trial is sponsored by UCB Pharma, which has 100 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00594165 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.